We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Bausch and Lomb Corporation | TSX:BLCO | Toronto | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.36 | -1.79% | 19.80 | 19.60 | 20.75 | 20.30 | 19.80 | 20.30 | 936 | 21:00:04 |
From Jul 2023 to Jul 2024
By Ben Glickman
Bausch + Lomb said Thursday it had acquired the Blink eye drop product line from Johnson & Johnson's Vision segment for $106.5 million, to be paid with cash on hand.
The deal follows another recent acquisition by the Canadian eye-care company to expand its portfolio. The Wall Street Journal reported that Bausch + Lomb is planning to buy Xiidra, a dry-eye drug, from Novartis for $1.75 billion, with potential add-on payments of up to $750 million.
Bausch + Lomb Chief Executive Brett Saunders, known for pursuing mergers and acquisitions, returned to the company in March after previously leading it from 2010 to 2013.
Write to Ben Glickman at ben.glickman@wsj.com
(END) Dow Jones Newswires
July 06, 2023 07:38 ET (11:38 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Bausch and Lomb Chart |
1 Month Bausch and Lomb Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
